PD1A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Broad-based Sales MomentumGrowth is broadening across the U.S., Cleanroom/scientific, and Healthcare businesses, indicating improving customer demand rather than reliance on one product area. A stronger mix of strategic and higher-value markets can support resilient revenue and reinforce Ansell’s global PPE position.
Margin And Productivity ExpansionHigher EBIT margins alongside recurring productivity savings demonstrate tangible operating improvement and give management more flexibility to absorb cost pressure. If sustained, these gains can strengthen earnings quality, fund strategic investment, and improve competitiveness across Ansell’s core markets.
Strong Cash Generation And LiquidityImproved cash conversion and lower net leverage provide financial capacity to support investment, dividends, and buybacks without placing undue strain on the balance sheet. The available liquidity also gives Ansell resilience while it manages ongoing operational and macroeconomic uncertainty.
Bears Say
Uneven Multi-year Revenue TrajectoryRecent growth has not yet established a consistently rising long-term revenue base, and full-year volumes remained slightly lower despite a stronger second half. This uneven demand pattern could make future margin and earnings improvement more dependent on pricing, mix, and execution.
Commodity And Raw-material Cost ExposureVolatile commodity inputs can pressure gross margins when cost increases occur faster than customer repricing or contract resets. Although Ansell has indicated that pricing can offset some effects, recurring input swings may create earnings variability and complicate margin planning.
Leverage Is Manageable But Not ConservativeThe balance sheet has improved, but absolute debt and the history of higher leverage leave less financial flexibility than a conservatively funded business would have. A weaker operating period could constrain capital allocation or increase the importance of maintaining strong cash conversion.
Ansell News
PD1A FAQ
What was Ansell’s price range in the past 12 months?
Currently, no data Available
What is Ansell’s market cap?
Ansell’s market cap is CHF3.64B.
When is Ansell’s upcoming earnings report date?
Ansell’s upcoming earnings report date is Feb 23, 2027 which is in 144 days.
How were Ansell’s earnings last quarter?
Ansell released its earnings results on Aug 23, 2026. The company reported CHF0.682 earnings per share for the quarter, beating the consensus estimate of CHF0.642 by CHF0.039.
Is Ansell overvalued?
According to Wall Street analysts Ansell’s price is currently Undervalued.
Does Ansell pay dividends?
Ansell does not currently pay dividends.
What is Ansell’s EPS estimate?
Ansell’s EPS estimate is 0.64.
How many shares outstanding does Ansell have?
Ansell has 140,313,830 shares outstanding.
What happened to Ansell’s price movement after its last earnings report?
Ansell reported an EPS of CHF0.682 in its last earnings report, beating expectations of CHF0.642. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ansell?
Currently, no hedge funds are holding shares in CH:PD1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ansell Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF22.75 (― Upside)
CHF22.75 (― Upside)
Insider Transactions
Bought Shares
Worth CHF165.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.48%
12-Months-Change
Fundamentals
Return on Equity
1.98%
Trailing 12-Months
Asset Growth
2.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ansell
Ansell Limited is a global enterprise that conceptualizes, innovates, and produces protective equipment for various industries across numerous regions, including Asia Pacific, Europe, the Middle East, Africa, the Americas, and the Caribbean. The company's operations are divided into two principal divisions: Healthcare and Industrial. The Healthcare division focuses on crafting and distributing products such as surgical, single-use, and examination gloves, alongside specialized cleanroom and sterile gloves and apparel. These offerings cater to a diverse clientele including medical facilities, surgical clinics, dental offices, veterinary practices, emergency services, research laboratories, and pharmaceutical and life science firms. Conversely, the Industrial segment provides hand and chemical protective gear designed for a wide array of demanding applications, from the automotive, chemical, and metal fabrication sectors to machinery, food processing, construction, mining, oil and gas industries, and first responders. Established in 1893 and headquartered in Richmond, Australia, the company was initially known as Pacific Dunlop Limited before rebranding to Ansell Limited in 2002. P. D. Holdings Pty. Ltd. currently operates as a subsidiary of Ansell Limited.
PD1A Company Deck
PD1A Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a clear majority of positive operational and financial outcomes — double-digit EPS growth, higher margins, strong cash conversion, U.S. and Cleanroom-led sales momentum, recurring cost savings (APIP $50M) and improved balance sheet metrics. Management also acknowledged and proactively managed notable headwinds (Middle East cost inflation, U.S. tariffs, commodity volatility, FX hedge losses and non‑cash impairments), and provided a constructive FY'27 EPS guidance range of $1.58–$1.70 with assumptions of continued volume/price momentum and ~$9M FX tailwind. On balance the positives — strong execution, margin expansion, cash generation and concrete operational improvements — outweigh the transient and manageable risks cited.View all CH:PD1A earnings summariesPD1A Stock 12 Month Forecast
Average Price Target
―Nanosonics Limited
―
Medical Developments International Limited
―
Trajan Group Holdings Ltd
―
CleanSpace Holdings Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―